Creative Biolabs Applauds Approved Oncolytic Virus Teserpaturev for Malignant Glioma Treatment

June 23 15:17 2021
On hearing the first approved oncolytic virus for brain cancer, Creative Biolabs, a prominent biotech company focusing on oncolytic virus therapy development, sincerely claps out this breakthrough of the cancer therapy pipeline with the mission of providing comprehensive services and products for research.

New York, USA – June 23, 2021 – The Japan Ministry of Health, Labour, and Welfare recently granted conditional approval of teserpaturev to treat malignant glioma, which inspires the oncolytic virus cancer therapy researchers and CROs that contribute to assisting oncolytic virotherapy pre-clinical studies.

Leveraging years of experience in cancer immunotherapy and virotherapy and a self-developed comprehensive oncolytic virus development platform, OncoVirapy™, Creative Biolabs has formed a library of pre-made oncolytic viruses. These oncolytic virus products have aided numerous in vitro and in vivo oncolytic virotherapy projects as reference agents and starting construct of backbone to generate new candidates.

Types of Oncolytic Viruses

The therapeutic oncolytic viruses with a broad DNA and RNA diversity can be genetically engineered or naturally occur to eliminate cancer cells. Adenovirus, herpes simplex virus, vaccinia virus, and vesicular stomatitis virus are the main four types used in current cancer clinical trials and research. For instance, the approved oncolytic virus teserpaturev against malignant glioma is triple-mutated, third-generation oncolytic herpes simplex virus type 1.

Herpes simplex virus

Herpes simplex virus (HSV), a human neurogenic dsDNA virus, can infect neurons with a life-long latent and allows for long-term transgene expression. To meet the needs of different projects, scientists at Creative Biolabs modify and purify oncolytic herpes simplex virus (oHSV) products to enhance the host immune response and reduce toxicity by gene knock-out.

The variants of pre-made oncolytic herpes simplex virus are covered in the oncolytic virus product collection of Creative Biolabs, which are prepared for scientific disease research of tumors, brain cancer, glioma, osteosarcoma, etc.

Vaccinia virus

Vaccinia virus is taken as the most promising live biotherapeutic agent due to its incredible oncolytic efficacy and potent antigen presenting capabilities. Moreover, foreign genes can be engineered into the viral genome in a stable status for long-term gene and immunizing antigen expression.

Creative Biolabs has designed and premade oncolytic vaccinia virus products for cancer therapy projects, including breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, glioblastoma, and lung cancer.

Others

Additionally, therapeutic transgenes like cytokines can be expressed in oncolytic viruses to enhance oncolytic efficacy. And oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests.

Go for more oncolytic virus products and services at https://www.creative-biolabs.com/oncolytic-virus.

About Creative Biolabs

Creative Biolabs is an expert in oncolytic virus design and construction, oncolytic virus product manufacturing, oncolytic virus engineering, and in vitro and in vivo validation studies of oncolytic virus. It has long shared a global reputation for providing customized and featured oncolytic virotherapy development services and products for various cancer therapy projects.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/oncolytic-virus